Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Gralise

Phase 3Small molecule

UUniversity of Rochester

Gralise is one of 30 small molecule programs targeting Amputation. It is currently in Phase 3.

1

Indications

3

Total Trials

0

Active Trials

29

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmputationActive, not recruiting

AmputationPhase 3

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Amputation

#DrugCompanyPhaseTrials

Acanya

Flagyl

DDePuy Orthopaedics

Peridex

DDexcel Pharma Technologies Ltd.

Ansaid

PPharmacia and Upjohn

Teicoplanin

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Depakote

Iodine

UUniversity of California, Los Angeles

Co-Amoxiclav

IImperial College London

Xylocaine

MMEDRx USA, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amputation1 trial

Once Daily Gabapentin in the Treatment of Post Amputation Pain

Unknown status·CChicago Anesthesia Pain Specialists·Phase 3·NCT01776671·16 enrolled

Chronic Pelvic Pain1 trial

Efficacy of Gralise® for Chronic Pelvic Pain

Terminated·SShirley Ryan AbilityLab·Phase 4·NCT01678911·11 enrolled

Spine Surgery1 trial

GRASSP: Gralise® for Spine Surgery Pain

Completed·UUniversity of Rochester·Phase 4·NCT01764464·53 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Gralise. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gralise compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gralise. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Rochester company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Rochester

Related News